文献速递帕金森病与运动障碍

氘代丁苯那嗪治疗迟发性运动障碍的随机对照试验:ARM-TD研究

Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD study.
PubMed 文献 · Neurology · 2017-04-26

主要终点显示氘代丁苯那嗪显著降低AIMS评分(-3.0 vs -1.6,p=0.019),且耐受性良好,精神科不良事件发生率低,未出现帕金森症状恶化。

要点

  • 氘代丁苯那嗪显著改善迟发性运动障碍患者的异常不自主运动。
  • 治疗12周时AIMS评分降低优于安慰剂,差异有统计学意义。
  • 精神科不良事件发生率低,未观察到帕金森症状加重。

核心结论

  • 在迟发性运动障碍患者中,氘代丁苯那嗪耐受性良好且显著减少异常运动。

主要发现

  • 主要终点:从基线至第12周AIMS评分变化,氘代丁苯那嗪组最小二乘均值(标准误)为-3.0(0.45),安慰剂组为-1.6(0.46),p=0.019。
  • CGIC治疗成功率氘代丁苯那嗪组48.2% vs 安慰剂组40.4%,差异无统计学意义。
  • 精神科不良事件发生率低:焦虑3.4% vs 6.8%,抑郁情绪/抑郁1.7% vs 1.7%,自杀意念0% vs 1.7%。
  • 第12周时两组UPDRS运动子量表均未观察到帕金森症状恶化。

关键数值与推荐

  • 纳入标准包括:盲法中心视频评估的AIMS评分≥6、精神疾病稳定、精神药物治疗稳定。
  • 主要终点为基线至第12周AIMS评分变化。

临床怎么用

  • 氘代丁苯那嗪可作为迟发性运动障碍的有效治疗选择,需关注精神科不良事件但发生率低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the efficacy and safety of deutetrabenazine as a treatment for tardive dyskinesia (TD). METHODS: One hundred seventeen patients with moderate to severe TD received deutetrabenazine or placebo in this randomized, double-blind, multicenter trial. Eligibility criteria included an Abnormal Involuntary Movement Scale (AIMS) score of ≥6 assessed by blinded central video rating, stable psychiatric illness, and stable psychoactive medication treatment. Primary endpoint was the change in AIMS score from baseline to week 12. Secondary endpoints included treatment success at week 12 on the Clinical Global Impression of Change (CGIC) and Patient Global Impression of Change. RESULTS: For the primary endpoint, deutetrabenazine significantly reduced AIMS scores from baseline to week 12 vs placebo (least-squares mean [standard error] -3.0 [0.45] vs -1.6 [0.46], p = 0.019). Treatment success on CGIC (48.2% vs 40.4%) favored deutetrabenazine but was not significant. Deutetrabenazine and placebo groups showed low rates of psychiatric adverse events: anxiety (3.4% vs 6.8%), depressed mood/depression (1.7% vs 1.7%), and suicidal ideation (0% vs 1.7%, respectively). In addition, no worsening in parkinsonism, as measured by the Unified Parkinson's Disease Rating Scale motor subscale, was noted from baseline to week 12 in either group. CONCLUSIONS: In patients with TD, deutetrabenazine was well tolerated and significantly reduced abnormal movements. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that in patients with TD, deutetrabenazine reduces AIMS scores.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Fernandez HH, Factor SA, Hauser RA, et al. Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD study. Neurology. 2017. PMID: 28446646. doi:10.1212/WNL.0000000000003960

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。